Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Assessing CEA evidence using shadow prices in Australia: NHMRC [9]

From: International lessons in new methods for grading and integrating cost effectiveness evidence into clinical practice guidelines

Ranking of evidence on costs Ranking of evidence on effects
High Low
Strong Recommend if: Recommend if:
<$70,000 per life-year <$30,000 per life-year
Do not recommend if Do not recommend if
>$100,000 per life-year >$70,000 per life-year
Weak Recommend if: Recommend if:
<$30,000 per life-year <$30,000 per life-year
Do not recommend if Do not recommend if
>$70,000 per life-year >$30,000 per life-year